The Immune Reset Revolution: CAR T-Cell Therapy Takes Centre Stage at EULAR 2026

Systemic lupus erythematosus (SLE) remains one of the most complex autoimmune diseases in rheumatology, characterised by chronic immune dysregulation, autoantibody production, and multi-organ inflammation. Although advances in biologic and targeted therapies have improved outcomes, a substantial proportion of patients continue to experience refractory disease, recurrent flares, progressive organ damage, and treatment-related toxicity. At the European Congress of Rheumatology (EULAR) 2026 in London, several studies presented compelling evidence supporting the use of chimeric antigen receptor (CAR) T-cell therapy as a transformative treatment for severe, treatment-resistant autoimmune diseases. Early-phase clinical data demonstrated that CD19-directed and dual-target CAR T-cell therapies can induce profound depletion of autoreactive B cells, leading to sustained drug-free remission, immune reconstitution, and significant clinical improvement in patients with refractory SLE, systemic sclerosis (SSc), rheumatoid arthritis (RA), and related autoimmune disorders. Notably, findings from the CARLYSLE study of obecabtagene autoleucel (obe-cel) and the Phase 1/2 relmacabtagene autoleucel (relma-cel) trial revealed encouraging efficacy and manageable safety profiles in patients with severe lupus, including many with lupus nephritis. These results support the concept that CAR T-cell therapy may act as an “immune reset,” rather than merely suppressing disease activity. This article reviews the scientific rationale, clinical evidence, safety considerations, and future implications of CAR T-cell therapy in SLE and refractory rheumatic diseases, with a focus on key presentations delivered at EULAR 2026.

Introduction

The treatment landscape for systemic lupus erythematosus has evolved considerably over the past two decades. Conventional immunosuppressive agents, including glucocorticoids, cyclophosphamide, mycophenolate mofetil, and azathioprine, have long formed the foundation of therapy. More recently, biologic agents such as belimumab and anifrolumab have improved disease management by targeting specific immune pathways.1

Despite these advances, a considerable unmet need persists. Many patients experience persistent disease activity despite multiple lines of therapy, while others develop irreversible organ damage due to lupus nephritis, neuropsychiatric lupus, or cardiovascular complications. Long-term exposure to corticosteroids also contributes substantially to morbidity.2

Against this backdrop, CAR T-cell therapy has emerged as one of the most exciting developments in autoimmune disease treatment. Originally developed for hematologic malignancies, CAR T-cell technology has now entered the field of rheumatology, where it is demonstrating the potential to induce deep and durable remissions in diseases previously considered incurable.3

At EULAR 2026, investigators from Europe and China presented a growing body of evidence suggesting that CAR T-cell therapy may fundamentally alter disease trajectories for patients with severe autoimmune disorders. The data support a paradigm shift from chronic immunosuppression toward immune system reprogramming and restoration.4

Understanding CAR T-Cell Therapy

CAR T-cell therapy involves collecting a patient's own T lymphocytes, genetically modifying them to express a chimeric antigen receptor (CAR), and reinfusing them following lymphodepleting chemotherapy. The engineered receptor enables T cells to recognise and eliminate specific target cells. In autoimmune diseases, most CAR T-cell strategies target CD19, a protein expressed on B cells (Figure 1).5

Figure 1. CAR T-cell Therapy Process5

The rationale is straightforward. B cells play a central role in autoimmune disease pathogenesis through autoantibody production, antigen presentation, cytokine secretion, and activation of autoreactive T cells.6

In SLE, autoreactive B cells generate pathogenic antibodies such as anti-double-stranded DNA antibodies that contribute directly to tissue injury. Eliminating these B cells may therefore interrupt multiple disease-driving mechanisms simultaneously. Importantly, CAR T-cell therapy appears capable of eliminating not only circulating B cells but also pathogenic memory B-cell populations that may evade conventional therapies such as rituximab. After depletion, the immune system may regenerate with a less autoreactive B-cell repertoire, creating what investigators increasingly describe as an "immune reset."4

Why an Immune Reset Matters in Lupus

Traditional lupus therapies suppress components of the immune system but generally do not eradicate the underlying autoreactive immune memory responsible for disease recurrence. Consequently, managing this condition requires a long-term approach because relapses are frequent. Over time, medications can cause toxic build-up in the body, and organ damage may unfortunately continue to advance even with ongoing treatment.3

CAR T-cell therapy offers a fundamentally different approach. By profoundly depleting pathogenic B cells and allowing new B-cell populations to develop, it may effectively reboot immune function. Several earlier studies published before EULAR 2026 demonstrated sustained remission in severe SLE following a single CAR T-cell infusion. The EULAR 2026 presentations extend these observations into larger patient populations and longer follow-up periods, strengthening confidence that durable immune reprogramming is achievable.7

CARLYSLE: Obecabtagene Autoleucel in Refractory Lupus

One of the most anticipated presentations at EULAR 2026 came from the CARLYSLE Phase I trial led by investigators at University College London and University College London Hospitals. The study evaluated obecabtagene autoleucel (obe-cel), a CD19-directed CAR T-cell therapy, in patients with severe refractory SLE who had failed multiple conventional and biologic therapies.4

Patient Characteristics4

Patients enrolled in CARLYSLE were:

• Aged 12 to 65 years

• Diagnosed with active severe SLE

• Refractory to multiple prior therapies

• Frequently affected by lupus nephritis

At the interim analysis presented at EULAR 2026, nine adult patients had received treatment. Most exhibited highly active disease and significant organ involvement.

Safety Findings4

One of the most encouraging aspects of the study was the favourable safety profile.

Investigators reported:

• No moderate or severe cytokine release syndrome (CRS)

• No immune effector cell-associated neurotoxicity syndrome (ICANS)

• One reversible dose-limiting liver toxicity

• Manageable infectious and haematologic adverse events

These findings are particularly important because CRS and neurotoxicity have historically represented major concerns with CAR T-cell therapies in oncology. The apparent reduction in severe toxicities raises the possibility that autoimmune disease patients may experience a more favourable risk-benefit profile.

Clinical Response4

Beyond safety, investigators observed substantial reductions in lupus disease activity following treatment. Clinical improvements were accompanied by profound depletion of CD19-positive B cells, consistent with the proposed mechanism of action. The findings suggest that immune reconstitution following B-cell depletion may translate into meaningful clinical benefit across multiple organ systems.

Relma-cel Phase 1/2 Trial: Deep Responses in Lupus

Another important EULAR 2026 presentation focused on relmacabtagene autoleucel (relma-cel), a CD19-directed autologous CAR T-cell therapy evaluated in China. The Phase 1 portion enrolled eight women with moderately to severely active SLE, all of whom had active organ involvement and had previously received at least two classes of standard lupus treatment.8

Remarkable Efficacy

Following relma-cel infusion, all patients achieved an SLE Responder Index 4 (SRI-4) response at six months, with six patients meeting the Lupus Low Disease Activity State (LLDAS) criteria and five achieving the Definition of Remission in SLE (DORIS) remission. Improvements in renal function and complement levels were also observed. These results are particularly notable given the severity of disease among enrolled patients and their history of treatment failure.8

Safety Outcomes

Safety outcomes were encouraging. No dose-limiting toxicities were reported. Adverse events were manageable, with CRS occurred in seven patients and ICANS in one patient. Importantly, investigators concluded that the therapy demonstrated both favourable safety and promising clinical efficacy, supporting progression into Phase 2 evaluation.8

Beyond Lupus: Expanding CAR T-Cell Therapy Across Rheumatology

A major theme at EULAR 2026 was the expansion of CAR T-cell therapy beyond SLE. Researchers presented data in systemic sclerosis, rheumatoid arthritis, inflammatory myopathies, and other severe autoimmune diseases, suggesting that immune-reset strategies may have broad applicability.7

Dual-Target CAR T Therapy in Systemic Sclerosis

Systemic sclerosis is characterised by immune activation, vasculopathy, and progressive fibrosis affecting the skin and internal organs.9 At EULAR 2026, investigators reported outcomes from eleven patients treated with dual-target CD19/B-cell maturation antigen (BCMA) CAR T-cell therapy. Results included:7

• Rapid and sustained B-cell depletion

• Significant improvement in skin thickness

• Improvement in functional disability scores

• Stabilisation or improvement of interstitial lung disease

• Regression of fibrotic lung abnormalities on imaging

• No disease flares during follow-up

Approximately 73% of patients achieved low disease activity, highlighting the potential of CAR T-cell therapy to modify disease progression even in severe fibrotic disorders.7

Rheumatoid Arthritis Data Signal Broader Potential

EULAR 2026 also featured findings from the COMPARE trial evaluating CD19-directed CAR T-cell therapy in treatment-refractory rheumatoid arthritis. Key observations included:7,10

• Substantial reductions in disease activity scores

• Significant declines in autoantibody levels

• Sustained remission in several patients

• Discontinuation of immunosuppressive therapy in most participants

Importantly, analyses suggested that CAR T-cell therapy eliminated pathogenic B-cell clones within synovial tissue, supporting the concept that immune reconstitution may extend beyond peripheral blood into diseased tissues.7,10

Mechanisms of Durable Remission

The durability of remission observed following CAR T-cell therapy raises important mechanistic questions. Several lines of evidence suggest that sustained responses are not merely a consequence of temporary B-cell depletion. Investigators have observed:11

• Elimination of autoreactive memory B cells

• Reduction in pathogenic autoantibodies

• Reconstitution of naïve B-cell populations

• Decreased interferon signalling

• Reprogramming of adaptive immune responses

• Reduction in inflammatory cytokine networks

Multi-omic analyses presented at EULAR 2026 further suggested coordinated remodelling of both immune and stromal pathways, particularly in systemic sclerosis, indicating that CAR T-cell therapy may exert effects extending beyond simple B-cell removal.11,12

Remaining Challenges

Despite remarkable enthusiasm, several challenges remain before CAR T-cell therapy can become routine clinical practice.

Cost and Accessibility

CAR T-cell therapy remains expensive and logistically intensive. Manufacturing personalised cellular products requires specialised facilities and extensive infrastructure.13

Long-Term Safety

Long-term follow-up is still limited. Questions remain regarding infection risk, secondary malignancies, hypogammaglobulinemia, and durability beyond several years.14-17

Patient Selection

The optimal patient population remains to be defined. Current studies largely focus on highly refractory disease, whereas future research may determine whether earlier intervention offers superior outcomes.18

Comparative Effectiveness

Randomised studies comparing CAR T-cell therapy against established biologics and targeted therapies will be critical for determining its place in treatment algorithms.17

Moving Forward

The field is evolving rapidly. Several innovations are under investigation:19,20

• Dual-target CAR constructs (CD19/BCMA)

• Faster manufacturing platforms

• Off-the-shelf allogeneic CAR products

• CAR-natural killer (CAR-NK) cell therapies

• Alternative autoimmune disease targets

As clinical experience expands, CAR T-cell therapy may ultimately move from a rescue therapy for refractory disease to a disease-modifying intervention capable of inducing sustained, treatment-free remission.21

Conclusion

The presentations delivered at EULAR 2026 represent a watershed moment in autoimmune disease therapeutics. Emerging evidence from the CARLYSLE study, the relma-cel Phase 1/2 trial, and investigations in systemic sclerosis and rheumatoid arthritis demonstrate that CAR T-cell therapy can induce deep, durable remissions in patients with severe, treatment-resistant rheumatic diseases. Unlike conventional immunosuppressive treatments, CAR T-cell therapy appears capable of fundamentally reprogramming immune function through elimination of autoreactive B cells and subsequent immune reconstitution.

Safety profiles reported to date have generally been manageable, with lower-than-expected rates of severe cytokine release syndrome and neurotoxicity. Although longer follow-up and larger randomised studies remain necessary, current findings strongly support the concept of an “immune reset” as a novel therapeutic paradigm.

If ongoing trials confirm these early results, CAR T-cell therapy may transform the management of SLE and other refractory autoimmune diseases, potentially enabling sustained remission, reduced treatment burden, and improved long-term outcomes for patients who currently have limited therapeutic options.

References

1. VKirou KA, et al. Front Immunol. 2022;13:980079. 2. Gandolfo S, et al. J Autoimmun. 2026;164:103617. 3. Mackensen A, et al. Nat Med. 2022;28(10):2124–32. 4. Medical Xpress. CAR T-cell therapy shows early promise in severe lupus. 15 June 2026. Available from: https://medicalxpress.com/news/2026-06-car-cell-therapy-early-severe.html. [Accessed 26 August 2026]. 5. Rocky Mountain MS Center. CAR T-Cell Therapy: A New Frontier for Treating Autoimmune Diseases. Available from: https://mscenter.org/article/car-t-cell-therapy-a-new-frontier-for-treating-autoimmune-diseases/. [Accessed 26 August 2026]. 6. Hampe CS. Scientifica (Cairo). 2012;2012:215308. 7. RheumNow. CAR-T Therapy: EULAR 2026 Conference Recap. 9 July 2026. Available from: https://rheumnow.com/news/car-t-therapy-eular-2026-conference-recap. [Accessed 26 August 2026]. 8. Wang Y, et al. J Autoimmun. 2025;157:103489. 9. Potjewijd J, et al. Expert Rev Clin Immunol. 2026;22(5):463–79. 10. Albach FN, et al. Nat Med . 2026 Aug 27. doi: 10.1038/s41591-026-04603-3. Online ahead of print. 11. JW Therapeutics. EULAR 2026: JW Therapeutics Presents Two Positive Study Results of Relma-cel for SLE and SSc at the European Congress of Rheumatology. 9 June 2026. Available from: https://www.jwtherapeutics.com/en/media/press-release/20260609/. [Accessed 26 August 2026]. 12. Mukherjee A. Clinical Immunology Communications. 2025; 8: 60–74. 13. Shah M, et al. Front Transplant. 2023;2:1238535. 14. Arya S and Shahid Z. Front Oncol. 2024;14:1398078. 15. Lee E, et al. Blood Res. 2026;61(1):30. 16. Bishop MR. Hematology Am Soc Hematol Educ Program. 2024;2024(1):109–15. 17. Cheng J, et al. Clin Exp Med. 2026;26(1):177. 18. Sioud M and Casey NP. Int J Mol Sci. 2026;27(2):909. 19. Cooper ML, et al. Off-the-Shelf CAR-T. In: Ghobadi A and DiPersio JF (eds). Gene and Cellular Immunotherapy for Cancer. Cancer Drug Discovery and Development. Humana, Cham; 2022. 20. Hoi A. Lancet. 2026;406(10522):2872–4. 21. Müller F, et al. Nat Med. 2026;32(3):1142–51.